Ignet

Gene Information

Gene symbol: SERPINA12

Gene name: serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12

HGNC ID: 18359

Synonyms: OL-64, Vaspin

Related Genes

#	Gene Symbol	Number of hits
1	ADIPOQ	1 hits
2	AHSA1	1 hits
3	AKT1	1 hits
4	APLN	1 hits
5	CCL2	1 hits
6	CD1A	1 hits
7	CFD	1 hits
8	CRP	1 hits
9	DNAJA1	1 hits
10	DNAJA2	1 hits
11	DNAJC1	1 hits
12	DPP4	1 hits
13	FABP4	1 hits
14	FGF1	1 hits
15	FGF19	1 hits
16	FGF21	1 hits
17	FTO	1 hits
18	GTF2A1	1 hits
19	HBB	1 hits
20	HSPA5	1 hits
21	ICAM1	1 hits
22	IL31RA	1 hits
23	IL6	1 hits
24	INS	1 hits
25	ITGAL	1 hits
26	ITLN1	1 hits
27	LEP	1 hits
28	MAPK8	1 hits
29	MKS1	1 hits
30	NAMPT	1 hits
31	NFKB1	1 hits
32	OPRD1	1 hits
33	PIK3CA	1 hits
34	PON1	1 hits
35	PON3	1 hits
36	PRKAA1	1 hits
37	RARRES2	1 hits
38	RBP4	1 hits
39	RETN	1 hits
40	SERPINA1	1 hits
41	STN	1 hits
42	TCF7	1 hits
43	TCF7L2	1 hits
44	TNF	1 hits
45	VCAM1	1 hits

Related Sentences

#	PMID	Sentence
1	11013303	The upregulated expression of well-characterized lipid metabolic enzymes, such as lipoprotein lipase, phosphoenolpyruvate carboxykinase, and cholesterol esterase, were observed in VAT of OLETF rats.
2	11013303	The C-terminal partial amino acid sequence of OL-64 revealed that it showed approximately 40% homology with alpha(1)-antitrypsin and it seemed to be a new member of the serine proteinase inhibitor (SERPIN) gene family.
3	16030142	Vaspin was barely detectable in rats at 6 wk and was highly expressed in adipocytes of visceral WATs at 30 wk, the age when obesity, body weight, and insulin levels peak in OLETF rats.
4	16030142	Administration of vaspin to obese CRL:CD-1 (ICR) (ICR) mice fed with high-fat high-sucrose chow improved glucose tolerance and insulin sensitivity reflected by normalized serum glucose levels.
5	16030142	It also led to the reversal of altered expression of genes relevant to insulin resistance, e.g., leptin, resistin, TNFalpha, glucose transporter-4, and adiponectin.
6	16030142	These findings indicate that vaspin exerts an insulin-sensitizing effect targeted toward WATs in states of obesity.
7	16030142	Vaspin was barely detectable in rats at 6 wk and was highly expressed in adipocytes of visceral WATs at 30 wk, the age when obesity, body weight, and insulin levels peak in OLETF rats.
8	16030142	Administration of vaspin to obese CRL:CD-1 (ICR) (ICR) mice fed with high-fat high-sucrose chow improved glucose tolerance and insulin sensitivity reflected by normalized serum glucose levels.
9	16030142	It also led to the reversal of altered expression of genes relevant to insulin resistance, e.g., leptin, resistin, TNFalpha, glucose transporter-4, and adiponectin.
10	16030142	These findings indicate that vaspin exerts an insulin-sensitizing effect targeted toward WATs in states of obesity.
11	16030142	Vaspin was barely detectable in rats at 6 wk and was highly expressed in adipocytes of visceral WATs at 30 wk, the age when obesity, body weight, and insulin levels peak in OLETF rats.
12	16030142	Administration of vaspin to obese CRL:CD-1 (ICR) (ICR) mice fed with high-fat high-sucrose chow improved glucose tolerance and insulin sensitivity reflected by normalized serum glucose levels.
13	16030142	It also led to the reversal of altered expression of genes relevant to insulin resistance, e.g., leptin, resistin, TNFalpha, glucose transporter-4, and adiponectin.
14	16030142	These findings indicate that vaspin exerts an insulin-sensitizing effect targeted toward WATs in states of obesity.
15	16298335	Recently, vaspin was identified as an adipokine with insulin-sensitizing effects, which is predominantly secreted from visceral adipose tissue in a rat model of type 2 diabetes.
16	16298335	In this study, we examined whether vaspin mRNA expression is a marker of visceral obesity and correlates with anthropometric and metabolic parameters in paired samples of visceral and subcutaneous adipose tissue from 196 subjects with a wide range of obesity, body fat distribution, insulin sensitivity, and glucose tolerance.
17	16298335	Subcutaneous vaspin mRNA expression is significantly correlated with WHR, fasting plasma insulin concentration, and glucose infusion rate during steady state of an euglycemic-hyperinsulinemic clamp.
18	16298335	Multivariate linear regression analysis revealed % body fat as strongest predictor of visceral vaspin and insulin sensitivity as strongest determinant of SC vaspin mRNA expression.
19	16298335	In conclusion, our data indicate that induction of human vaspin mRNA expression in adipose tissue is regulated in a fat depot-specific manner and could be associated with parameters of obesity, insulin resistance, and glucose metabolism.
20	16298335	Recently, vaspin was identified as an adipokine with insulin-sensitizing effects, which is predominantly secreted from visceral adipose tissue in a rat model of type 2 diabetes.
21	16298335	In this study, we examined whether vaspin mRNA expression is a marker of visceral obesity and correlates with anthropometric and metabolic parameters in paired samples of visceral and subcutaneous adipose tissue from 196 subjects with a wide range of obesity, body fat distribution, insulin sensitivity, and glucose tolerance.
22	16298335	Subcutaneous vaspin mRNA expression is significantly correlated with WHR, fasting plasma insulin concentration, and glucose infusion rate during steady state of an euglycemic-hyperinsulinemic clamp.
23	16298335	Multivariate linear regression analysis revealed % body fat as strongest predictor of visceral vaspin and insulin sensitivity as strongest determinant of SC vaspin mRNA expression.
24	16298335	In conclusion, our data indicate that induction of human vaspin mRNA expression in adipose tissue is regulated in a fat depot-specific manner and could be associated with parameters of obesity, insulin resistance, and glucose metabolism.
25	16298335	Recently, vaspin was identified as an adipokine with insulin-sensitizing effects, which is predominantly secreted from visceral adipose tissue in a rat model of type 2 diabetes.
26	16298335	In this study, we examined whether vaspin mRNA expression is a marker of visceral obesity and correlates with anthropometric and metabolic parameters in paired samples of visceral and subcutaneous adipose tissue from 196 subjects with a wide range of obesity, body fat distribution, insulin sensitivity, and glucose tolerance.
27	16298335	Subcutaneous vaspin mRNA expression is significantly correlated with WHR, fasting plasma insulin concentration, and glucose infusion rate during steady state of an euglycemic-hyperinsulinemic clamp.
28	16298335	Multivariate linear regression analysis revealed % body fat as strongest predictor of visceral vaspin and insulin sensitivity as strongest determinant of SC vaspin mRNA expression.
29	16298335	In conclusion, our data indicate that induction of human vaspin mRNA expression in adipose tissue is regulated in a fat depot-specific manner and could be associated with parameters of obesity, insulin resistance, and glucose metabolism.
30	16298335	Recently, vaspin was identified as an adipokine with insulin-sensitizing effects, which is predominantly secreted from visceral adipose tissue in a rat model of type 2 diabetes.
31	16298335	In this study, we examined whether vaspin mRNA expression is a marker of visceral obesity and correlates with anthropometric and metabolic parameters in paired samples of visceral and subcutaneous adipose tissue from 196 subjects with a wide range of obesity, body fat distribution, insulin sensitivity, and glucose tolerance.
32	16298335	Subcutaneous vaspin mRNA expression is significantly correlated with WHR, fasting plasma insulin concentration, and glucose infusion rate during steady state of an euglycemic-hyperinsulinemic clamp.
33	16298335	Multivariate linear regression analysis revealed % body fat as strongest predictor of visceral vaspin and insulin sensitivity as strongest determinant of SC vaspin mRNA expression.
34	16298335	In conclusion, our data indicate that induction of human vaspin mRNA expression in adipose tissue is regulated in a fat depot-specific manner and could be associated with parameters of obesity, insulin resistance, and glucose metabolism.
35	16298335	Recently, vaspin was identified as an adipokine with insulin-sensitizing effects, which is predominantly secreted from visceral adipose tissue in a rat model of type 2 diabetes.
36	16298335	In this study, we examined whether vaspin mRNA expression is a marker of visceral obesity and correlates with anthropometric and metabolic parameters in paired samples of visceral and subcutaneous adipose tissue from 196 subjects with a wide range of obesity, body fat distribution, insulin sensitivity, and glucose tolerance.
37	16298335	Subcutaneous vaspin mRNA expression is significantly correlated with WHR, fasting plasma insulin concentration, and glucose infusion rate during steady state of an euglycemic-hyperinsulinemic clamp.
38	16298335	Multivariate linear regression analysis revealed % body fat as strongest predictor of visceral vaspin and insulin sensitivity as strongest determinant of SC vaspin mRNA expression.
39	16298335	In conclusion, our data indicate that induction of human vaspin mRNA expression in adipose tissue is regulated in a fat depot-specific manner and could be associated with parameters of obesity, insulin resistance, and glucose metabolism.
40	17018519	Adipocyte-derived "adipokines" such as adiponectin, leptin, and visceral adipose tissue-derived serine protease inhibitor (vaspin) exert hormone-like activities at the systemic level.
41	17018519	Moreover we detected a number of established adipokines such as adiponectin and plasminogen activator inhibitor 1.
42	17018519	In addition to plasminogen activator inhibitor 1, these included pigment epithelium-derived factor (confirmed by Western immunoblot), placental thrombin inhibitor, pregnancy zone protein, and protease C1 inhibitor.
43	17331067	Some genes that have become accepted as contributors to diabetes risk include: calpain 10, peroxisome proliferator-activated receptor-gamma, ATP-sensitive inwardly rectifying potassium channel subunit Kir6.2, hepatocyte nuclear factor 4alpha and hepatic transcription factor 1.
44	17331067	In particular, we highlight recent reports of associations between Type 2 diabetes and the transcription factor 7-like 2 gene, associations with micro-opioid receptor and supressor of cytokine signaling 2 genes, and expression and functional analyses of adipokines vaspin and retinol binding protein 4.
45	18230903	Adiposederived proinflammatory cytokines, vasoactive peptides, coagulation and complement factors, visfatin, vaspin and retinol-binding protein signal through paracrine and hormonal mechanisms.
46	18321232	Vaspin: a novel serpin with insulin-sensitizing effects.
47	18375437	Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
48	18726871	Vaspin has recently been identified as novel adipokine with high expression in adipose tissue of obese and type 2 diabetic subjects and with potentially insulin-sensitising properties.
49	18800627	[Vaspin and insulin resistance].
50	18800627	Administration of recombinant vaspin into high fat high sucrose (HFHS) chow-induced obese ICR mice improved glucose tolerance and insulin sensitivity.
51	18800627	[Vaspin and insulin resistance].
52	18800627	Administration of recombinant vaspin into high fat high sucrose (HFHS) chow-induced obese ICR mice improved glucose tolerance and insulin sensitivity.
53	19362933	Several cytokines, tumor necrosis factor-alpha and its soluble receptor forms, sTNFR1 and sTNFR2, resistin, retinol-binding protein 4, plasminogen activator inhibitor, lipocain 1 inhibit the signalization of insulin receptor causing insulin resistance in target tissues, mainly in adipose, liver and muscle, brain, endothelial as well as in pancreatic beta-cells.
54	19362933	However, many other proteins produced by the fat tissue, such as adiponectin, visfatin, vaspin, apelin, omentin and chemerin enhance the signal transmission of the receptor.
55	19362933	Recently discovered common mechanisms leading to insulin and cytokine resistance in obesity and type 2 diabetes mellitus, e.g. protein family of suppressor of cytokine signaling (SOCS) are also discussed.
56	19801900	Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells.
57	19801900	We therefore assessed the effects of vaspin on basal and TNF-alpha-stimulated human umbilical vein ECs.
58	19801900	Vaspin (10-100 ng/ml, 24 hr) had no effects on both basal ECs morphology and TNF-alpha-induced (10 ng/ml, 24 hr) morphological damages.
59	19801900	Vaspin did not inhibit the TNF-alpha (20 min) activation of JNK, p38 and NF-kappaB, but only slightly inhibited Akt.
60	19801900	Furthermore, vaspin did not decrease the TNF-alpha (24 hr) induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, endothelial selectin, and cyclooxygenase-2 protein expression as well as monocyte chemotactic protein-1, tissue factor, and plasmogen activator inhibitor-1 mRNA expression.
61	19801900	The present results indicate that vaspin has no effects on normal ECs, and can not prevent TNF-alpha-induced inflammatory injury.
62	19801900	Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells.
63	19801900	We therefore assessed the effects of vaspin on basal and TNF-alpha-stimulated human umbilical vein ECs.
64	19801900	Vaspin (10-100 ng/ml, 24 hr) had no effects on both basal ECs morphology and TNF-alpha-induced (10 ng/ml, 24 hr) morphological damages.
65	19801900	Vaspin did not inhibit the TNF-alpha (20 min) activation of JNK, p38 and NF-kappaB, but only slightly inhibited Akt.
66	19801900	Furthermore, vaspin did not decrease the TNF-alpha (24 hr) induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, endothelial selectin, and cyclooxygenase-2 protein expression as well as monocyte chemotactic protein-1, tissue factor, and plasmogen activator inhibitor-1 mRNA expression.
67	19801900	The present results indicate that vaspin has no effects on normal ECs, and can not prevent TNF-alpha-induced inflammatory injury.
68	19801900	Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells.
69	19801900	We therefore assessed the effects of vaspin on basal and TNF-alpha-stimulated human umbilical vein ECs.
70	19801900	Vaspin (10-100 ng/ml, 24 hr) had no effects on both basal ECs morphology and TNF-alpha-induced (10 ng/ml, 24 hr) morphological damages.
71	19801900	Vaspin did not inhibit the TNF-alpha (20 min) activation of JNK, p38 and NF-kappaB, but only slightly inhibited Akt.
72	19801900	Furthermore, vaspin did not decrease the TNF-alpha (24 hr) induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, endothelial selectin, and cyclooxygenase-2 protein expression as well as monocyte chemotactic protein-1, tissue factor, and plasmogen activator inhibitor-1 mRNA expression.
73	19801900	The present results indicate that vaspin has no effects on normal ECs, and can not prevent TNF-alpha-induced inflammatory injury.
74	19801900	Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells.
75	19801900	We therefore assessed the effects of vaspin on basal and TNF-alpha-stimulated human umbilical vein ECs.
76	19801900	Vaspin (10-100 ng/ml, 24 hr) had no effects on both basal ECs morphology and TNF-alpha-induced (10 ng/ml, 24 hr) morphological damages.
77	19801900	Vaspin did not inhibit the TNF-alpha (20 min) activation of JNK, p38 and NF-kappaB, but only slightly inhibited Akt.
78	19801900	Furthermore, vaspin did not decrease the TNF-alpha (24 hr) induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, endothelial selectin, and cyclooxygenase-2 protein expression as well as monocyte chemotactic protein-1, tissue factor, and plasmogen activator inhibitor-1 mRNA expression.
79	19801900	The present results indicate that vaspin has no effects on normal ECs, and can not prevent TNF-alpha-induced inflammatory injury.
80	19801900	Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells.
81	19801900	We therefore assessed the effects of vaspin on basal and TNF-alpha-stimulated human umbilical vein ECs.
82	19801900	Vaspin (10-100 ng/ml, 24 hr) had no effects on both basal ECs morphology and TNF-alpha-induced (10 ng/ml, 24 hr) morphological damages.
83	19801900	Vaspin did not inhibit the TNF-alpha (20 min) activation of JNK, p38 and NF-kappaB, but only slightly inhibited Akt.
84	19801900	Furthermore, vaspin did not decrease the TNF-alpha (24 hr) induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, endothelial selectin, and cyclooxygenase-2 protein expression as well as monocyte chemotactic protein-1, tissue factor, and plasmogen activator inhibitor-1 mRNA expression.
85	19801900	The present results indicate that vaspin has no effects on normal ECs, and can not prevent TNF-alpha-induced inflammatory injury.
86	19801900	Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells.
87	19801900	We therefore assessed the effects of vaspin on basal and TNF-alpha-stimulated human umbilical vein ECs.
88	19801900	Vaspin (10-100 ng/ml, 24 hr) had no effects on both basal ECs morphology and TNF-alpha-induced (10 ng/ml, 24 hr) morphological damages.
89	19801900	Vaspin did not inhibit the TNF-alpha (20 min) activation of JNK, p38 and NF-kappaB, but only slightly inhibited Akt.
90	19801900	Furthermore, vaspin did not decrease the TNF-alpha (24 hr) induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, endothelial selectin, and cyclooxygenase-2 protein expression as well as monocyte chemotactic protein-1, tissue factor, and plasmogen activator inhibitor-1 mRNA expression.
91	19801900	The present results indicate that vaspin has no effects on normal ECs, and can not prevent TNF-alpha-induced inflammatory injury.
92	20045145	The objective of the study was to investigate serum levels of the insulin-sensitizing adipokine vaspin in patients with gestational diabetes mellitus (GDM) and preeclampsia (PE) as compared with healthy controls of similar gestational age.
93	20045145	Circulating vaspin levels are not significantly different between GDM, PE, and control subjects and do not correlate with insulin sensitivity in pregnant subjects.
94	20045145	The objective of the study was to investigate serum levels of the insulin-sensitizing adipokine vaspin in patients with gestational diabetes mellitus (GDM) and preeclampsia (PE) as compared with healthy controls of similar gestational age.
95	20045145	Circulating vaspin levels are not significantly different between GDM, PE, and control subjects and do not correlate with insulin sensitivity in pregnant subjects.
96	20505674	We evaluated body weight, body mass index, SBP, DBP, glycated hemoglobin, fasting plasma glucose, M value, adiponectin (ADN), resistin (r), retinol-binding protein 4, visfatin, vaspin and high-sensitivity C-reactive protein (Hs-CRP) at their baseline values and after 6 and 12 months of treatment.
97	20505674	Retinol binding protein-4, r, and the vaspin value decreased in the candesartan group but not in olmesartan group.
98	20505674	We evaluated body weight, body mass index, SBP, DBP, glycated hemoglobin, fasting plasma glucose, M value, adiponectin (ADN), resistin (r), retinol-binding protein 4, visfatin, vaspin and high-sensitivity C-reactive protein (Hs-CRP) at their baseline values and after 6 and 12 months of treatment.
99	20505674	Retinol binding protein-4, r, and the vaspin value decreased in the candesartan group but not in olmesartan group.
100	21031343	Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
101	21372376	In this manuscript, I summarize our recent findings on the vascular effects of 5 newly identified adipocytokines (omentin, visfatin, nesfatin, vaspin, and chemerin), with a special focus on 1) vascular contractile reactivity, and 2) vascular inflammatory response/injury.
102	21422197	Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans.
103	21738955	Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.
104	21738955	Visfatin exerts insulin-mimetic effects, decreases plasma glucose levels and regulates cell energy balance.
105	21738955	Vaspin expression in human adipose tissue seems to be a compensatory mechanism associated with obesity and insulin resistance.
106	21738955	Vaspin suppresses leptin, tumor necrosis factor (TNF)-α and resistin expression.
107	21738955	Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.
108	21738955	Visfatin exerts insulin-mimetic effects, decreases plasma glucose levels and regulates cell energy balance.
109	21738955	Vaspin expression in human adipose tissue seems to be a compensatory mechanism associated with obesity and insulin resistance.
110	21738955	Vaspin suppresses leptin, tumor necrosis factor (TNF)-α and resistin expression.
111	21738955	Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.
112	21738955	Visfatin exerts insulin-mimetic effects, decreases plasma glucose levels and regulates cell energy balance.
113	21738955	Vaspin expression in human adipose tissue seems to be a compensatory mechanism associated with obesity and insulin resistance.
114	21738955	Vaspin suppresses leptin, tumor necrosis factor (TNF)-α and resistin expression.
115	21770819	Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis.
116	21802961	Vaspin has been regarded as a novel adipokine with potential insulin sensitizing properties.
117	21802961	In T2DM patients, fasting plasma vaspin concentrations were significantly decreased after rosiglizatone therapy for 12 weeks (1.19±0.74 vs. 0.91±0.54 μg/L, P<0.05), accompanied with significant amelioration of insulin sensitivity and glucose control.
118	21802961	Plasma vaspin levels were positively associated with the fasting insulin and the homeostasis model assessment of IR (HOMA-IR).
119	21802961	And rosiglitazone therapy decreased plasma vaspin levels through glucose and insulin sensitivity regulation.
120	21802961	Vaspin has been regarded as a novel adipokine with potential insulin sensitizing properties.
121	21802961	In T2DM patients, fasting plasma vaspin concentrations were significantly decreased after rosiglizatone therapy for 12 weeks (1.19±0.74 vs. 0.91±0.54 μg/L, P<0.05), accompanied with significant amelioration of insulin sensitivity and glucose control.
122	21802961	Plasma vaspin levels were positively associated with the fasting insulin and the homeostasis model assessment of IR (HOMA-IR).
123	21802961	And rosiglitazone therapy decreased plasma vaspin levels through glucose and insulin sensitivity regulation.
124	21802961	Vaspin has been regarded as a novel adipokine with potential insulin sensitizing properties.
125	21802961	In T2DM patients, fasting plasma vaspin concentrations were significantly decreased after rosiglizatone therapy for 12 weeks (1.19±0.74 vs. 0.91±0.54 μg/L, P<0.05), accompanied with significant amelioration of insulin sensitivity and glucose control.
126	21802961	Plasma vaspin levels were positively associated with the fasting insulin and the homeostasis model assessment of IR (HOMA-IR).
127	21802961	And rosiglitazone therapy decreased plasma vaspin levels through glucose and insulin sensitivity regulation.
128	21802961	Vaspin has been regarded as a novel adipokine with potential insulin sensitizing properties.
129	21802961	In T2DM patients, fasting plasma vaspin concentrations were significantly decreased after rosiglizatone therapy for 12 weeks (1.19±0.74 vs. 0.91±0.54 μg/L, P<0.05), accompanied with significant amelioration of insulin sensitivity and glucose control.
130	21802961	Plasma vaspin levels were positively associated with the fasting insulin and the homeostasis model assessment of IR (HOMA-IR).
131	21802961	And rosiglitazone therapy decreased plasma vaspin levels through glucose and insulin sensitivity regulation.
132	22139797	Consistent with that higher vaspin serum concentrations and increased vaspin mRNA expression in human adipose tissue were found to be associated with obesity, insulin resistance, and type 2 diabetes in humans.
133	22139797	However, the mechanisms how vaspin secretion may be linked to deterioration of glucose metabolism and insulin sensitivity are not entirely understood.
134	22139797	Administration of vaspin to obese mice improves glucose tolerance, insulin sensitivity, and reduces food intake.
135	22139797	Thus, identification of the proteases, which are inhibited by vaspin may lead to the development of novel strategies in the treatment of obesity, diabetes and insulin resistance.
136	22139797	Consistent with that higher vaspin serum concentrations and increased vaspin mRNA expression in human adipose tissue were found to be associated with obesity, insulin resistance, and type 2 diabetes in humans.
137	22139797	However, the mechanisms how vaspin secretion may be linked to deterioration of glucose metabolism and insulin sensitivity are not entirely understood.
138	22139797	Administration of vaspin to obese mice improves glucose tolerance, insulin sensitivity, and reduces food intake.
139	22139797	Thus, identification of the proteases, which are inhibited by vaspin may lead to the development of novel strategies in the treatment of obesity, diabetes and insulin resistance.
140	22139797	Consistent with that higher vaspin serum concentrations and increased vaspin mRNA expression in human adipose tissue were found to be associated with obesity, insulin resistance, and type 2 diabetes in humans.
141	22139797	However, the mechanisms how vaspin secretion may be linked to deterioration of glucose metabolism and insulin sensitivity are not entirely understood.
142	22139797	Administration of vaspin to obese mice improves glucose tolerance, insulin sensitivity, and reduces food intake.
143	22139797	Thus, identification of the proteases, which are inhibited by vaspin may lead to the development of novel strategies in the treatment of obesity, diabetes and insulin resistance.
144	22139797	Consistent with that higher vaspin serum concentrations and increased vaspin mRNA expression in human adipose tissue were found to be associated with obesity, insulin resistance, and type 2 diabetes in humans.
145	22139797	However, the mechanisms how vaspin secretion may be linked to deterioration of glucose metabolism and insulin sensitivity are not entirely understood.
146	22139797	Administration of vaspin to obese mice improves glucose tolerance, insulin sensitivity, and reduces food intake.
147	22139797	Thus, identification of the proteases, which are inhibited by vaspin may lead to the development of novel strategies in the treatment of obesity, diabetes and insulin resistance.
148	22539588	Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population.
149	22837305	Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex.
150	22837305	Here, we show that visceral adipose tissue-derived serine protease inhibitor (vaspin) binds to cell-surface 78-kDa glucose-regulated protein (GRP78), which is recruited from ER to plasma membrane under ER stress.
151	22837305	The complex formation of vaspin, GRP78, and murine tumor cell DnaJ-like protein 1 (MTJ-1) (DnaJ homolog, subfamily C, member 1) on plasma membrane was confirmed by cell-surface labeling with biotin and immunoprecipitation in liver tissues and H-4-II-E-C3 cells.
152	22837305	The addition of recombinant human vaspin in the cultured H-4-II-E-C3 cells also increased the phosphorylation of Akt and AMP-activated protein kinase (AMPK) in a dose-dependent manner, and anti-GRP78 antibodies completely abrogated the vaspin-induced upregulation of pAkt and pAMPK.
153	22837305	Vaspin is a novel ligand for cell-surface GRP78/MTJ-1 complex, and its subsequent signals exert beneficial effects on ER stress-induced metabolic dysfunctions.
154	22837305	Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex.
155	22837305	Here, we show that visceral adipose tissue-derived serine protease inhibitor (vaspin) binds to cell-surface 78-kDa glucose-regulated protein (GRP78), which is recruited from ER to plasma membrane under ER stress.
156	22837305	The complex formation of vaspin, GRP78, and murine tumor cell DnaJ-like protein 1 (MTJ-1) (DnaJ homolog, subfamily C, member 1) on plasma membrane was confirmed by cell-surface labeling with biotin and immunoprecipitation in liver tissues and H-4-II-E-C3 cells.
157	22837305	The addition of recombinant human vaspin in the cultured H-4-II-E-C3 cells also increased the phosphorylation of Akt and AMP-activated protein kinase (AMPK) in a dose-dependent manner, and anti-GRP78 antibodies completely abrogated the vaspin-induced upregulation of pAkt and pAMPK.
158	22837305	Vaspin is a novel ligand for cell-surface GRP78/MTJ-1 complex, and its subsequent signals exert beneficial effects on ER stress-induced metabolic dysfunctions.
159	22837305	Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex.
160	22837305	Here, we show that visceral adipose tissue-derived serine protease inhibitor (vaspin) binds to cell-surface 78-kDa glucose-regulated protein (GRP78), which is recruited from ER to plasma membrane under ER stress.
161	22837305	The complex formation of vaspin, GRP78, and murine tumor cell DnaJ-like protein 1 (MTJ-1) (DnaJ homolog, subfamily C, member 1) on plasma membrane was confirmed by cell-surface labeling with biotin and immunoprecipitation in liver tissues and H-4-II-E-C3 cells.
162	22837305	The addition of recombinant human vaspin in the cultured H-4-II-E-C3 cells also increased the phosphorylation of Akt and AMP-activated protein kinase (AMPK) in a dose-dependent manner, and anti-GRP78 antibodies completely abrogated the vaspin-induced upregulation of pAkt and pAMPK.
163	22837305	Vaspin is a novel ligand for cell-surface GRP78/MTJ-1 complex, and its subsequent signals exert beneficial effects on ER stress-induced metabolic dysfunctions.
164	22837305	Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex.
165	22837305	Here, we show that visceral adipose tissue-derived serine protease inhibitor (vaspin) binds to cell-surface 78-kDa glucose-regulated protein (GRP78), which is recruited from ER to plasma membrane under ER stress.
166	22837305	The complex formation of vaspin, GRP78, and murine tumor cell DnaJ-like protein 1 (MTJ-1) (DnaJ homolog, subfamily C, member 1) on plasma membrane was confirmed by cell-surface labeling with biotin and immunoprecipitation in liver tissues and H-4-II-E-C3 cells.
167	22837305	The addition of recombinant human vaspin in the cultured H-4-II-E-C3 cells also increased the phosphorylation of Akt and AMP-activated protein kinase (AMPK) in a dose-dependent manner, and anti-GRP78 antibodies completely abrogated the vaspin-induced upregulation of pAkt and pAMPK.
168	22837305	Vaspin is a novel ligand for cell-surface GRP78/MTJ-1 complex, and its subsequent signals exert beneficial effects on ER stress-induced metabolic dysfunctions.
169	22837305	Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex.
170	22837305	Here, we show that visceral adipose tissue-derived serine protease inhibitor (vaspin) binds to cell-surface 78-kDa glucose-regulated protein (GRP78), which is recruited from ER to plasma membrane under ER stress.
171	22837305	The complex formation of vaspin, GRP78, and murine tumor cell DnaJ-like protein 1 (MTJ-1) (DnaJ homolog, subfamily C, member 1) on plasma membrane was confirmed by cell-surface labeling with biotin and immunoprecipitation in liver tissues and H-4-II-E-C3 cells.
172	22837305	The addition of recombinant human vaspin in the cultured H-4-II-E-C3 cells also increased the phosphorylation of Akt and AMP-activated protein kinase (AMPK) in a dose-dependent manner, and anti-GRP78 antibodies completely abrogated the vaspin-induced upregulation of pAkt and pAMPK.
173	22837305	Vaspin is a novel ligand for cell-surface GRP78/MTJ-1 complex, and its subsequent signals exert beneficial effects on ER stress-induced metabolic dysfunctions.
174	22982016	Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report.
175	22982016	The present study was aimed to investigate the impact of chemerin rs17173608 and vaspin rs2236242 gene polymorphisms with the risk of MeS in a sample of Iranian population.
176	22982016	A significant protection against MeS was found for vaspin rs2236242 in allele and genotypes (Odd Ratio [OR]=0.52; 95% confidence interval [CI]=0.37-0.72; p=0.0001, T vs A; OR=0.49; 95%CI=0.29-0.82; p=0.007, TT vs TA and OR=0.17; 95%CI=0.07-0.40; p<0.0001, TT vs AA).
177	22982016	Our finding showed positive association between chemerin rs17173608 polymorphism and risk of MeS (χ(2)=7.70, p=0.021).
178	22982016	In conclusion, our data suggest for the first time a significant association between vaspin rs2236242 and chemerin rs17173608 polymorphisms and the MeS in Zahedan, southeast Iran.
179	22982016	Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report.
180	22982016	The present study was aimed to investigate the impact of chemerin rs17173608 and vaspin rs2236242 gene polymorphisms with the risk of MeS in a sample of Iranian population.
181	22982016	A significant protection against MeS was found for vaspin rs2236242 in allele and genotypes (Odd Ratio [OR]=0.52; 95% confidence interval [CI]=0.37-0.72; p=0.0001, T vs A; OR=0.49; 95%CI=0.29-0.82; p=0.007, TT vs TA and OR=0.17; 95%CI=0.07-0.40; p<0.0001, TT vs AA).
182	22982016	Our finding showed positive association between chemerin rs17173608 polymorphism and risk of MeS (χ(2)=7.70, p=0.021).
183	22982016	In conclusion, our data suggest for the first time a significant association between vaspin rs2236242 and chemerin rs17173608 polymorphisms and the MeS in Zahedan, southeast Iran.
184	22982016	Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report.
185	22982016	The present study was aimed to investigate the impact of chemerin rs17173608 and vaspin rs2236242 gene polymorphisms with the risk of MeS in a sample of Iranian population.
186	22982016	A significant protection against MeS was found for vaspin rs2236242 in allele and genotypes (Odd Ratio [OR]=0.52; 95% confidence interval [CI]=0.37-0.72; p=0.0001, T vs A; OR=0.49; 95%CI=0.29-0.82; p=0.007, TT vs TA and OR=0.17; 95%CI=0.07-0.40; p<0.0001, TT vs AA).
187	22982016	Our finding showed positive association between chemerin rs17173608 polymorphism and risk of MeS (χ(2)=7.70, p=0.021).
188	22982016	In conclusion, our data suggest for the first time a significant association between vaspin rs2236242 and chemerin rs17173608 polymorphisms and the MeS in Zahedan, southeast Iran.
189	22982016	Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report.
190	22982016	The present study was aimed to investigate the impact of chemerin rs17173608 and vaspin rs2236242 gene polymorphisms with the risk of MeS in a sample of Iranian population.
191	22982016	A significant protection against MeS was found for vaspin rs2236242 in allele and genotypes (Odd Ratio [OR]=0.52; 95% confidence interval [CI]=0.37-0.72; p=0.0001, T vs A; OR=0.49; 95%CI=0.29-0.82; p=0.007, TT vs TA and OR=0.17; 95%CI=0.07-0.40; p<0.0001, TT vs AA).
192	22982016	Our finding showed positive association between chemerin rs17173608 polymorphism and risk of MeS (χ(2)=7.70, p=0.021).
193	22982016	In conclusion, our data suggest for the first time a significant association between vaspin rs2236242 and chemerin rs17173608 polymorphisms and the MeS in Zahedan, southeast Iran.
194	23160181	Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL.
195	23160181	Three novel genes (FTO, ITGAL, and SERPINA12) and the PON gene cluster had SNPs associated with PON1 arylesterase (AREase) activity.
196	23160181	PON1 (P = 2.24 × 10(-4)), PON3 (P = 0.022), FTO (P = 0.019), and SERPINA12 (P = 0.039) had both common and rare variants associated with PON1 AREase.
197	23160181	ITGAL variants were associated with PON1 activity when using weighted sequence kernel association testing (SKAT) analysis (P = 2.63 × 10(-3)).
198	23160181	We present novel findings that common and rare variants in FTO, SERPINA12, and ITGAL predict PON1 activity.
199	23160181	Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL.
200	23160181	Three novel genes (FTO, ITGAL, and SERPINA12) and the PON gene cluster had SNPs associated with PON1 arylesterase (AREase) activity.
201	23160181	PON1 (P = 2.24 × 10(-4)), PON3 (P = 0.022), FTO (P = 0.019), and SERPINA12 (P = 0.039) had both common and rare variants associated with PON1 AREase.
202	23160181	ITGAL variants were associated with PON1 activity when using weighted sequence kernel association testing (SKAT) analysis (P = 2.63 × 10(-3)).
203	23160181	We present novel findings that common and rare variants in FTO, SERPINA12, and ITGAL predict PON1 activity.
204	23160181	Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL.
205	23160181	Three novel genes (FTO, ITGAL, and SERPINA12) and the PON gene cluster had SNPs associated with PON1 arylesterase (AREase) activity.
206	23160181	PON1 (P = 2.24 × 10(-4)), PON3 (P = 0.022), FTO (P = 0.019), and SERPINA12 (P = 0.039) had both common and rare variants associated with PON1 AREase.
207	23160181	ITGAL variants were associated with PON1 activity when using weighted sequence kernel association testing (SKAT) analysis (P = 2.63 × 10(-3)).
208	23160181	We present novel findings that common and rare variants in FTO, SERPINA12, and ITGAL predict PON1 activity.
209	23160181	Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL.
210	23160181	Three novel genes (FTO, ITGAL, and SERPINA12) and the PON gene cluster had SNPs associated with PON1 arylesterase (AREase) activity.
211	23160181	PON1 (P = 2.24 × 10(-4)), PON3 (P = 0.022), FTO (P = 0.019), and SERPINA12 (P = 0.039) had both common and rare variants associated with PON1 AREase.
212	23160181	ITGAL variants were associated with PON1 activity when using weighted sequence kernel association testing (SKAT) analysis (P = 2.63 × 10(-3)).
213	23160181	We present novel findings that common and rare variants in FTO, SERPINA12, and ITGAL predict PON1 activity.
214	23225237	Gender-dependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: a randomized clinical trial.
215	23225237	The aim of the study was to assess the effects of metformin on serum concentrations of vaspin and adiponectin in diabetes.
216	23225237	Healthy subjects had significantly higher adiponectin levels, but lower concentrations of serum vaspin (p<0.001 in all cases).
217	23225237	Vaspin and adiponectin concentrations were 23% and 26% higher in women compared with men.
218	23225237	Gender-dependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: a randomized clinical trial.
219	23225237	The aim of the study was to assess the effects of metformin on serum concentrations of vaspin and adiponectin in diabetes.
220	23225237	Healthy subjects had significantly higher adiponectin levels, but lower concentrations of serum vaspin (p<0.001 in all cases).
221	23225237	Vaspin and adiponectin concentrations were 23% and 26% higher in women compared with men.
222	23225237	Gender-dependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: a randomized clinical trial.
223	23225237	The aim of the study was to assess the effects of metformin on serum concentrations of vaspin and adiponectin in diabetes.
224	23225237	Healthy subjects had significantly higher adiponectin levels, but lower concentrations of serum vaspin (p<0.001 in all cases).
225	23225237	Vaspin and adiponectin concentrations were 23% and 26% higher in women compared with men.
226	23225237	Gender-dependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: a randomized clinical trial.
227	23225237	The aim of the study was to assess the effects of metformin on serum concentrations of vaspin and adiponectin in diabetes.
228	23225237	Healthy subjects had significantly higher adiponectin levels, but lower concentrations of serum vaspin (p<0.001 in all cases).
229	23225237	Vaspin and adiponectin concentrations were 23% and 26% higher in women compared with men.
230	23241684	Novel adipokines secreted from adipocytes such as retinol binding protein-4 (RBP-4), vaspin, omentin, chemerin, fibroblast growth factor 21 (FGF21), adipocyte fatty acid-binding protein (A-FABP) and dipeptidyl peptidase 4 (DPP4) demonstrate pleiotropic activity and their insulin-sensitizing or enhancing insulin resistance properties have not been clearly confirmed yet.
231	23449848	Effect of statin therapy on vaspin levels in type 2 diabetic patients.
232	23497782	Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-κB signaling pathways.
233	23772224	These adipokines including leptin, visfatin, resistin, apelin, vaspin, and retinol binding protein-4 can regulate inflammatory responses and contribute to the pathogenesis of diabetes.
234	23772224	These effects are mediated by key inflammatory signaling molecules including activated serine kinases such as c-Jun N-terminal kinase and serine kinases inhibitor κB kinase and insulin signaling molecules including insulin receptor substrates, protein kinase B (PKB, also known as Akt), and nuclear factor kappa B.
235	23970879	Macrophages play a role in the inflammatory process by secreting many cytokines such as tumor necrosis factor alpha, interleukin-6, resistin, and retinol binding protein-4.
236	23970879	More metabolic regulators, such as fibroblast growth factor (FGF)21, FGF19, FGF1, vaspin, and visfatin have now been discovered but their exact roles in human diseases are still unclear.